Irreversible myelosuppression after fludarabine-melphalan conditioning: observations in patients with graft rejection. uri icon

Overview

publication date

  • June 1, 2004

Research

keywords

  • Antineoplastic Agents, Alkylating
  • Graft Rejection
  • Immunosuppressive Agents
  • Melphalan
  • Vidarabine

Identity

Scopus Document Identifier

  • 2542450948

Digital Object Identifier (DOI)

  • 10.1182/blood-2004-02-0583

PubMed ID

  • 15155474

Additional Document Info

volume

  • 103

issue

  • 11